Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.
Chronic Lymphocytic Leukemia
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry|
- Identify and summarize patterns in therapeutic regimens [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]Describe practice patterns of first line therapy regimens and subsequent therapeutic strategies in patients initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting
- Clinical outcomes [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]Provide insight into therapeutic regimens and therapy sequence in clinical practice as they relate to clinical outcomes in patients initiated on first-line, second-line or subsequent therapies for CLL.
- Summarize Effectiveness of Treatment Regimens [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]Describe any differences in effectiveness associated with treatment regimens, including first-line regimens and subsequent therapeutic strategies in patients actively treated for CLL
- Health Related Quality of Life Measures Related to Therapeutic Regimens [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]Describe the health-related quality of life of patients actively treated for CLL, and to explore the association of HRQoL with therapeutic regimens, sequences and clinical outcomes.
|Study Start Date:||September 2009|
|Estimated Study Completion Date:||September 2017|
|Estimated Primary Completion Date:||September 2017 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01081015
|Contact: Kristen Sullivanemail@example.com|
Show 248 Study Locations
|Study Director:||Kenneth Foon, MD||Celgene Corporation|